OCEA (Ocean Biomedical) Total Stockholders Equity: $-92.40 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Ocean Biomedical Total Stockholders Equity?

Ocean Biomedical OCEA -20.00% Total Stockholders Equity is $-92.40 Mil as of Mar. 2025.

Ocean Biomedical's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $-92.40 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Ocean Biomedical's Book Value per Share for the quarter that ended in Mar. 2025 was $-0.56. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Ocean Biomedical's Debt-to-Equity for the quarter that ended in Mar. 2025 was -0.10.


Ocean Biomedical  (OTCPK:OCEA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Ocean Biomedical's Book Value per Share for the quarter that ended in Mar. 2025 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Ocean Biomedical's Debt-to-Equity for the quarter that ended in Mar. 2025 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocean Biomedical Total Stockholders Equity Related Terms


Ocean Biomedical Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Ocean Biomedical's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocean Biomedical Total Stockholders Equity Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
Get a 7-Day Free Trial -1.89 105.26 -10.82 -90.76 -97.62

Ocean Biomedical Quarterly Data
Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.78 -92.74 -98.09 -97.62 -92.40
What does a Total Stockholders Equity of $-92.40 Mil mean?
Ocean Biomedical (OCEA) has a Total Stockholders Equity of $-92.40 Mil as of Mar. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Ocean Biomedical and its competitors.
Is Ocean Biomedical's Total Stockholders Equity too high?
Ocean Biomedical's current Total Stockholders Equity is $-92.40 Mil.
How does Ocean Biomedical's Total Stockholders Equity compare to SIGY and ENDV?
Ocean Biomedical's Total Stockholders Equity of $-92.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Ocean Biomedical and its competitors. Ocean Biomedical's current Total Stockholders Equity is $-92.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocean Biomedical stock overvalued right now?
Ocean Biomedical (OCEA) has a current Total Stockholders Equity of $-92.40 Mil. The current Total Stockholders Equity is $-92.40 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Ocean Biomedical (OCEA), the current Total Stockholders Equity is $-92.40 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ocean Biomedical Business Description

Address 55 Claverick Street, Room 325, Providence, RI, USA, 02903
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.